PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp...

32
PROFILE PERUSAHAAN Company Profile 3 21 PT MILLENNIUM PHARMACON INTERNATIONAL Tbk Laporan Tahunan 2018 | Annual Report DEFY GRAVITY

Transcript of PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp...

Page 1: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

PROFILEPERUSAHAAN

Company Profile

3

21PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 2: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

PROFIL PERUSAHAAN COMPANY PROFILE

22

DATA PERUSAHAAN CORPORATE DATA

03

Nama dan Alamat Kantor Pusat Manajemen dan Operasi Operation and Management Head Office Name and Address

PT MILLENNIUM PHARMACON INTERNATIONAL TbkGedung Bank Panin Pusat, Lantai 9

Jl. Jenderal Sudirman, Senayan - Jakarta 10270Telp : (62-21) 7278-8907Fax : (62-21) 722-8090

Kontak Perusahaan untuk Pemegang Saham dan InvestorCompany Contact for Shareholders and Investors

Email : investor.rela�[email protected]

Website : h�p://www.mpi-pharmaniaga.co.id

Industri Sektor Sector Industry

Distribusi dan PenjualanSales and Distribu�on

Jumlah CabangNumber of Branches

32 Cabang 32 Branches

Jumlah Gudang Number of Warehouses

1 Gudang Pusat 1 Central Warehouse

Ijin Emisi SahamStock Emission License

No. SI-090/SHM/MK.10/1990

Tanggal 22 Maret 1990 Dated March 22nd, 1990

Tanggal Pencatatan Saham di Bursa EfekStock Lis�ng Date of the Stock Exchange

7 Mei 1990 May 7��, 1990

Kode Saham Ticker Code

SDCP

Akuntan Publik Terda�arRegistered Public Accountant

Anggota Morrison Internasional Member of Morison Interna�onal

Tjahjadi & Tamara

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 3: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

23

Perseroan didirikan di Jakarta pada tanggal 20 Oktober 1952 oleh Bapak Soedarpo Sastrosatomo dan Ibu Minarsih Soedarpo Sastrosatomo Wiranatakusumah dengan nama N .V. P e r u s a h a a n D a g a n g S O E D A R P O CORPORATION, berdasarkan Akta Perseroan Terbatas N.V. Perusahaan Dagang Soedarpo Corpora�on No.32 tertanggal 20 Oktober 1952 yang diperbaiki dengan Akta Perubahan No.14 tertanggal 5 Mei 1953, keduanya dibuat di hadapan Raden Meester Soewandi, Notaris di Jakarta, yang telah disahkan oleh Menteri Kehakiman Republik Indonesia berdasarkan Surat Keputusan No.J.A.5/43/20 tanggal 27 Mei 1953, dida�arkan dalam register di Kantor Panitera Pengadilan Negeri di Jakarta pada tanggal 5 Juni 1953 di bawah No.683, dan diumumkan dalam Berita Negara Republik Indonesia No.56 tanggal 14 Juli 1953, Tambahan No.421.

Perubahan nama N.V. Perusahaan Dagang Soedarpo Corpora�on menjadi PT NVPD Soedarpo Corpora�on Tbk sebagaimana yang termaktub dalam Akta No. 182 tanggal 21 Februari 1990, dibuat oleh Rahar� Sudjardja�, S.H., Notaris di Jakarta yang telah memperoleh pengesahan dari Menteri Kehakiman Republik Indonesia dengan Keputusan Nomor C2-1252-HT- 01.04.TH.90 tanggal 7 Maret 1990 serta telah diumumkan dalam Berita Negara Republik Indonesia No. 31 tanggal 17 April 1990 Tambahan No. 1418.

RIWAYAT SINGKAT PERUSAHAAN COMPANY HISTORY

Profil Perusahaan Company Profile

The company was founded in Jakarta on October 20��, 1952 by Mr. Soedarpo Sastrosatomo and Mrs. Minarsih Soedarpo Sastrosatomo Wiranatakusumah under the name NV of the SOEDARPO CORPORATION Trading Company, based on the Deed. 14 dated May 5��, 1953, made before Raden Meester Soewandi, Notary in Jakarta, which was approved by the Minister of Jus�ce of the Republic of Indonesia through Decree No.JA5 / 43/20 dated May 27��, 1953, registered in the register at the Registrar's Office of the District Court in Jakarta on June 5th, 1953 under No. 683, and announced in the State Gaze�e of the Republic of Indonesia No.56 dated July 14��, 1953, Supplement No.421.

The change of name N.V. The Soedarpo Corpora�on Trading Company into PT NVPD Soedarpo Corpora�on Tbk was made according to the notarial Deed No. 182 dated February 21��, 1990, by Rahar� Sudjardja�, S.H., a Notary in Jakarta who had obtained approval from the Minister of Jus�ce of the Republic of Indonesia with Decree No. C2-1252-HT-01.04.TH.90 dated March 7��, 1990 and has been announced in the State Gaze�e of the Republic of Indonesia No. 31 dated April 17��, 1990 Supplement No. 1418

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Untuk menyesuaikan dengan UU PT No.1 Tahun 1995 dan UU Pasar Modal, Anggaran Dasar Perseroan diubah dengan Akta No.22 tanggal 18 Nopember 1997 yang dibuat di hadapan Notaris Rahar� Sudjardja�,S.H., yang telah memperoleh pengesahan dari Menteri Kehakiman Republik Indonesia dengan Keputusan No.C2 - 2183.HT.01.04.TH.90 tanggal 24 Maret 1998 dan telah diumumkan dalam BNRI No.49 tanggal 19 Juni 1998, Tambahan No.3270.

To conform to Law No. 1 of 1995 and the Capital Market Law, the Ar�cles of Associa�on of the Company were amended by Deed No. 22 dated November 18�� , 1997 which was made before Notary Rahar� Sudjardja�, S.H., who had been approved by the Minister of Jus�ce of the Republic of Indonesia with Decree No. C2-2183.HT.01.04.TH.90 dated March 24�� , 1998 and was announced at the BNRI No.49 dated June 19th , 1998, Supplement No. 3270.

Berdasarkan persetujuan Menteri Keuangan Republik Indonesia dengan Surat Keputusan No. SI-090/SHM/MK.10/1990 tanggal 22 Maret 1990, Perseroan telah menjual sebagian sahamnya kepada masyarakat, dan pada tanggal 7 Mei 1990 telah dicatatkan pada Bursa Efek di Indonesia sebanyak 3.500.000 lembar yang merupakan 38,46% dari modal saham yang ditempatkan dan disetor penuh.

Based on approval from the Ministry of Finance of the Republic of Indonesia in the le�er of Decision No.SI-090/SHM/MK.10/1990 dated March 22ⁿ�, 1990 the Company had sold its shares to the public and in May 7��, 1990 the Company has listed 3,500,000 shares on the Indonesian Stock Exchanges represen�ng 38.46% of the total outstanding shares.

Page 4: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

24

03

Profil Perusahaan Company Profile

Perseroan melakukan peningkatan modal dasar melalui Penawaran Umum Terbatas dengan persetujuan pemegang saham sebagaimana dinyatakan dalam Rapat Umum Pemegang Saham Tahunan (RUPST) di Jakarta pada tanggal 15 Mei 2000. Dalam Penawaran Umum Terbatas tesebut, Modal Dasar Perseroan di�ngkatkan menjadi sebanyak 145.600.000 (seratus empat puluh lima juta enam ratus ribu) saham dengan nilai nominal Rp 500,- (lima ratus Rupiah). Peningkatan modal dasar tersebut dibuat di hadapan Amrul Partomuan Pohan, S.H., LL.M., Notaris di Jakarta dalam Akta No. 33 tanggal 15 Mei 2000, sebagaimana diumumkan dalam BNRI No. 61 tanggal 1 Agustus 2000, Tambahan No. 4135.

Berdasarkan Akta No. 23 tanggal 9 Juni 2000 yang dibuat di hadapan Amrul Partomuan Pohan, S .H. , LL .M. , Notar is d i Jakarta sebagaimana diumumkan dalam BNRI No. 73 tanggal 12 September 2000, Tambahan No. 5340, PT. NVPD Soedarpo Corpora�on diubah namanya menjadi PT. Millennium Pharmacon Interna�onal Tbk.

The Company increased its authorized capital through a Limited Public Offering (Right Issue exercise) with the approval of the shareholders as stated at the Annual General Mee�ng of Shareholders (AGMS) in Jakarta on May 15�� , 2000. In that Limited Public Offering, the Company's authorized capital was increased to 145,600,000 (one hundred forty five million six hundred thousand) shares with a nominal value of Rp 500, - (five hundred Rupiah). The increase in authorized capital was made before Amrul Partomuan Pohan, S.H., LL.M., Notary in Jakarta in Deed No. 33 dated May 15�� , 2000, as announced in BNRI No. 61 dated August 1��,

2000, Supplement No. 4135.

Based on Deed No. 23 dated June 9�� , 2000 made before Amrul Partomuan Pohan, S.H., LL.M., Notary in Jakarta as announced in BNRI No. 73 dated September 12��, 2000, Supplement No. 5340, PT. NVPD Soedarpo Corpora�on was r e n a m e d P T. M i l l e n n i u m P h a r m a c o n Interna�onal Tbk.

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Jumlah saham hasil PUT II tersebut diumumkan kepada publik oleh PT Bursa Efek Jakarta dalam surat pengumumannya No. Peng- 455/BEJ.EEM/08-2002 tanggal 6 Agustus 2002 dimana disebutkan bahwa jumlah saham Perseroan yang tercatat di PT Bursa Efek Jakarta adalah sebanyak 728.000.000 saham dengan nilai nominal Rp 100.

Total amount of shares as a result of the second Limited General Offer exercise has been

announced to public by Jakarta Stock Exchange limited on its le�er No. Peng-455/BEJ.EEM/08-2002 dated August 6��, 2002. The announcement stated that total shares of the Company in Jakarta Stock Exchange is 728,000,000 shares at the nominal of Rp 100 per share.

Pa d a ta n g ga l 2 4 J u n i 2 0 0 2 Pers ero a n menyelenggarakan RUPSLB dimana disetujui rencana Direksi Perseroan untuk melakukan Penawaran Umum Terbatas Kedua (PUT II) dengan menerbitkan Hak Memesan Efek Terlebih Dahulu (HMETD) untuk sejumlah 182.000.000 saham, pemberian wewenang kepada Dewan Komisaris Perseroan untuk meningkatkan Modal Ditempatkan dan Disetor Perseroan dan sekaligus mengubah ketentuan Pasal 4 ayat 2 Anggaran Dasar Perseroan sebagaimana termaktub dalam Akta No. 37 tanggal 24 Juni 2002, dan Peningkatan Modal Dasar Perseroan dari semula sebesar Rp 72.800.000.000 menjadi Rp 218.400.000.000 sekaligus merubah Pasal 4 ayat 1 Anggaran Dasar Perseroan.

In June 24�� , 2002, the Company had done EGM which has been agreed in the EGM to conduct a Limited General Offer (Right Issue Exercise) II by issuing the Right to Order Stock Preemp�vely (HMETD) Issue exercise by issuing new shares amoun�ng to 182,000,000 shares, give authoriza�on to the Board of Commissioners to increase issued capital and paid-up capital simultaneously to change certainty of Ar�cle 4 verse 2 of the Company Ar�cles of Associa�on as stated in deed No. 37 dated June 24�� , 2002, and to increase autorized capital from Rp 72,800,000,000 to Rp 218,400,000,000 simultaneously to change Ar�cle 4 verse 1 of the Company Ar�cles of Associa�on.

Page 5: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

25

Profil Perusahaan Company Profile

Untuk mengan�sipasi persaingan global, Perseroan menggandeng investor strategis dari Malaysia yaitu Pharmaniaga Berhad (Bhd) melalui anak perusahaannya, Esteem Interpoint Sdn Bhd (Esteem), yang sekarang bernama Pharmaniaga Interna�onal Corpora�on Sdn Bhd.

Pada tanggal 8 Juni 2004 telah ditandatangani Nota Kesepakatan antara PT Tigamitra Mul�karya dan Esteem, Malaysia yang isinya bahwa Esteem mengambil alih 55% saham dari total modal disetor PT Millennium Pharmacon Interna�onal Tbk.

Esteem melalui tender offer pada tanggal 3 Desember 2004 yang diumumkan melalui 2 (dua) harian berperedaran nasional telah mengambil alih saham dari PT Tigamitra Mul�karya sebanyak 400.404.000 lembar atau sekitar 55% dari seluruh saham yang telah dikeluarkan oleh Perseroan.

To an�cipate global compe��on, the Company cooperates with strategic investors from Malaysia, namely Pharmaniaga Berhad (Bhd) through its subsidiary, Esteem Interpoint Sdn Bhd (Esteem), which is now called Pharmaniaga Interna�onal Corpora�on Sdn Bhd.

In June 8��, 2004, a Memorandum of Under-standing was signed between PT Tiga mitra Mul�karya and Esteem, Malaysia sta�ng that Esteem shall acquire 55% shares from the total paid-up capital of PT Millennium Pharmacon Interna�onal Tbk.

Esteem through a tender offer in December 3��, 2004 announced through 2 na�onal daily newspapers, has acquired shares from PT Tigamitra Mul�karya totaling 400,404,000 shares or about 55% from the total shares issued by the Company.

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Pada tanggal 11 September 2017 Perseroan telah menyelenggarakan RUPSLB dimana disetujui rencana Direksi Perseroan untuk melakukan Penawaran Umum Terbatas III (PUT III) dengan menerbitkan Hak Memesan EfekTerlebih Dahulu (HMETD) untuk sejumlah 546.000.000 saham. Pemberian wewenang kepada Dewan Komisaris Perseroan untuk meningkatkan Modal Ditempatkan dan Disetor Perseroan dan sekaligus mengubah ketentuan Pasal 4 ayat 2 Anggaran Dasar Perseroan sebagaimana termaktub dalam Akta No. 196 tanggal 20 Desember 2017, dari semula sebesar Rp 72.800.000.000 menjadi Rp 127.400.000.000.

In September 11��, 2017, the Company had done EGM which has been agreed in the EGM to conduct a Limited General Offer (Right Issue Exercise) III by issuing new shares with the Right to Order Stock Preemp�vely (HMETD) to 546.000.000 shares, to give authoriza�on to the Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Ar�cle 4 verse 2 of the Company Ar�cles of Associa�on as stated in deed No. 196 dated December 20��, 2017.

Jumlah saham hasil PUT III tersebut diumumkan kepada publik oleh PT Bursa Efek Jakarta dalam surat pemberitahuan No.S-06592/BEI.PP3/11- 2017 tanggal 30 November 2017 yang disebutkan bahwa jumlah saham Perseroan yang tercatat di PT Bursa Efek Jakarta bertambah sebanyak 546.000.000 saham menjadi 1.274.000.000 dengan nilai nominal Rp 100.

Total amount of shares as a result of the Third Limited General Offer exercise has been announced to public by Jakarta Stock Exchange limited on its le�er No. No.S-06592/BEI.PP3/11-2017 dated November 30��, 2017. The announcement stated that total shares of the Company in Jakarta Stock Exchange is 1.274.000.000 shares at the nominalof Rp 100 per share.

Page 6: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

03

Perusahaan bergerak dibidang usaha distribusi produk farmasi, suplemen makanan, dan alat kesehatan dengan cakupan seluruh wilayah Indonesia, beroperasi dengan 32 kantor cabang dan 1 gudang pusat.Perusahaan mendistribusikan produk dari prinsipal dalam negeri dan luar negeri. Untuk produk ethical disitribusikan ke masyarakat melalui apo�k dan rumah sakit, sedangkan untuk produk OTC ( over the counter) didistribusikan melalui apotik, toko obat dan pasar modern.

Company is engaged in the distribu�on of pharmaceu�cal products, food supplements and medical devices with na�onwide coverage. It operates with 32 branches and 1 central warehouse.

The Company distributes products for both domestic and foreign principals. Ethical products are distributed to the community through pharmacies and hospitals, while OTC (over the counter) products are distributed through pharmacy, drug stores and modern markets.

Profil Perusahaan Company Profile

Kegiatan Usaha Menurut Anggaran Dasar Business Activities According to the Latest Articles of Association

Dalam Akta Pernyataan Keputusan Rapat Umum Pemegang Saham PT. Millennium Pharmacon Interna�onal Tbk No. 36 tanggal 6 April 2018 Pasal 3, maksud dan tujuan serta kegiatan usaha adalah sebagai berikut:

1. Maksud dan tujuan Perseroan ialah :

Berusaha dalam bidang perdagangan,industri dan jasa.

In the Deed of Decision of the Decision of the General Mee�ng of Shareholders of PT. Millennium Pharmacon Interna�onal Tbk No. 36 April 6��, 2018 Ar�cle 3, the purpose and objec�ves and business ac�vi�es are as follows:

1. The purpose and objec�ve of the Company are:

Trying in the fields of trade, industry andservices

26 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

BIDANG USAHA COMPANY BUSINESS SECTORS

Jejak LangkahMilestone

Page 7: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

ii. Suppor�ng business ac�vi�es

a. Industrial business and distribu�on ofproducts from these industries, both athome and abroad;

b. Do service business in general, exceptservices in the legal field.

c. Running other businesses related to thebusiness sectors of the main businessac�vi�es above in accordance with theapplicable laws and regula�ons.

ii. Kegiatan Usaha Penunjang :

a. Usaha industri serta menyalurkan hasilproduksi dari industri-industri tersebut,baik di dalam maupun di luar negeri;

b. Melakukan usaha jasa pada umumnya,kecuali jasa dalam bidang hukum.

c. Menjalankan usaha-usaha lain yangberkaitan dengan bidang usaha kegiatanusaha utama di atas sesuai denganperaturan perundang-undangan yangberlaku.

1. Penjualan dan distribusi2. Pemasaran3. Logis�k

1. Distribu�on and Sales2. Marke�ng3. Logis�cs

1. Obat Resep2. Obat Non-resep3. Alat Kesehatan

1. Prescrip�on Medicines2. Non prescrip�on medicines3. Medical devices

JasaServices

ProdukProducts

27

Produk dan Jasa Products and Services

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

2. Untuk mencapai maksud dan tujuan tersebutdi atas Perseroan dapat melaksanakankegiatan usaha sebagai berikut :

i. Kegiatan Usaha Utama :

Menjalankan usaha di bidangperdagangan, yang melipu� perdagangansetempat (lokal) termasuk penjualanlangsung kepada konsumen/penjualaneceran (retail), antar pulau (interinsulair),ekspor dan impor (perdagangan obat-obatan untuk manusia dan hewan), jamutradisional, obat herbal, kosme�ka,makanan dan minuman, alat kesehatan,perbekalan kesehatan rumah tangga(PKRT), baik untuk perhitungan sendiriatau tanggungan sendiri atau tanggungansendiri maupun perhitungan atautanggungan pihak lain atas dasar komisiatau imbalan lainnya, dan ber�ndaksebagai distributor, agen, penyalur, dangrosir dari berbagai macam barang,

2. To achieve the above objec�ves and objec�vesthe Company can carry out business ac�vi�esas follows:

I. Main Business Ac�vi�es

Running a business in the field of trade, which includes local (local) trade including direct sales to consumers / retail (retail), inter-island (interinsulair), export and import (trade in drugs for humans and animals), t rad i�onal herbal medic ine , herbal medicines, cosme�cs, food and beverage, medical devices, household health supplies (PKRT), either for own calcula�on or own responsibility or own responsibility or calcula�on or dependence of other par�es on the basis of commissions or other benefits, and act as distributors, agents, distributors, and wholesalers of various items.

Page 8: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

PRINSIPAL-PRINSIPAL PRINCIPALS

03

Profil Perusahaan Company Profile

28

PRINSIPAL-PRINSIPAL PRINCIPALS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

No. No.

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

PT. ANUGRAH AGROTEKINDO

PT. APEX PHARMA

PT. BIO AXION HEALTHINDO

PT. DANPAC PHARMA

PT. DIPA PHARMALAB INTERSAINS

PT. DIPA PHARMALAB INTERSAINS (CHD)

PT. ERRITA PHARMA

PT. GLOBAL DISPO MEDIKA

PT. GLOBAL SUCCESS CHAIN

PT. GRACIA PHARMINDO

PT. GUARDIAN PHARMATAMA

PT.IKA PHARMINDO PUTRAMAS

PT. LAPI LABORATORIES

PT. MARION SAM

PT. MEDIHOP

PT. MEIJI INDONESIA PHARMACEAUTICAL INDUSTRIES

PT. MEPROFARM PHARMACEAUTICAL INDUSTRIES

PT. METISKA FARMA

PT. NAVITA INTI PRIMA

PT. NULAB PHARMACEUTICAL INDONESIA

PT. NUTRIFOOD INDONESIA

PT. NUTRINDO JAYA ABADI

PT. NUTRINDO GRAHA HUSADA UTAMA PT.

NUTRISAINS

PT. PHAROS INDONESIA

PT. PRIMA MEDIKA LABORATORIES

PT.PROMEDRAHARDJO FARMASI INDUSTRI

PT. PUSPA PHARMA

PT. SIMEX PHARMACEAUTICAL INDONESIA

PT. STARNEGY

PT. STERIL MEDICAL INDONESIA

PT. TEGUHSINDO LESTARITAMA

NAMA PERUSAHAANCompany Name

PT. MERSIFARMA TIRMAKU MERCUSANA (PT.TIARA KENCANA)

NAMA PERUSAHAANCompany Name

Page 9: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

29PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

ALAMAT DAN JARINGAN KANTOR CABANG ADDRESSES AND WORK AREAS OPERATIONAL MAP

Gudang Pusat Jakarta

Jl. Tipar No. 20 Cakung, Jakarta

Timur Telp. 0812 1544322

Jakarta IJl. Depsos No. 67-70, BintaroTelp. (021) 734-1862, 7388-1367, 7388-6375,

7388-6376, 7388-6382Fax (021) 7388-6378

Jakarta IIJl. Panjang No. 83 HH, Jakarta Barat Telp. (021) 56952205/ 56952204Fax (021) 5633254

BekasiRuko Grand Mal Bekasi Blok D20-D21Telp. (021) 885-5720, 885-7039, 8895-9632Fax. (021) 885-4844

Tangerang Pergudangan Sinar Ha�Jl. Sinar ha� No. 88 Blok H dan I kel. Sukaja�Kec. Karawaci Tangerang, Banten.Telp. (021) 553-4287, 5579-1233Fax. (021) 021 557887071

BogorKomplek Ruko Perum Haji Kota Bogor Blok B12-B14Jl. Tumenggung Wiradiredja RT/RW 002/008Kel. Cimahpar, Kec. Bogor Utara – Kota BogorTelp. (0251) 756-3122, 756-3123Fax (0251) 756-3121

BandungJl. Jenderal Sudirman No. 656Telp. (022) 6030371, 6034715Fax (022) 6045526

Pusat:

Gedung Panin Bank Center Lt 9 Jl. Jend Sudirman, Senayan 10270Telp. 021- 727 88907 / 727 88906Fax. 021- 722 8090

Cirebon

Jl. Kesambi No. 78 RT/04/04Telp. (0231) 231615Fax (0231) 231614

PurwokertoJl. Mangun Jaya No. 272, Purwokerto Tlp. 639878; 632878 Fax. 639878

SemarangJl. Pamularsih No. 107Telp. (024) 760-2020Fax (024) 760-9905

YogyakartaJl. Dumung Ni.111 A, KaranggayamCatur Tunggal, Depok, SlemanTelp. (0274) 565-107, 565-258Fax (0274) 565-258

SoloJl. Dr. Radjiman No.652B, Pajang-LaweyanTelp. (0271) 7066-581, 739-327, 739-554Fax (0271) 722-468

SurabayaJl. Kalibokor Selatan No.152Telp. (031) 502-6210, 502-6674, 502-9638Fax (031) 501-5003

Sidoarjo Jl. Kar�ni No. 70 A Sidoarjo Telp. (031) 997 02838 / 997 02839 Fax. (031) 997 02420

MalangJl. Sunandar Priyo Sudarmo No.20 DTelp. (0341) 405-620, 405-624Fax (0341) 405-511

KediriJl. Masjid Al-Huda No.04 NgadirejoTelp. (0354) 673-188/ 673-189Fax (0354) 4674569

JemberJl. Kertanegara No.210Telp. (0331) 410008, 484494Fax (0331) 421-647

Page 10: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

03

30 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Banda AcehJl. Nyak Adam Kamil II, No.76 E-H Peuni�, BaiturrahmanTelp. (0651) 22625/26/32Fax (0651) 22630

MedanJln. Beringin No.2 Ringroad, Kel. Sunggal, Kec.Medan Sunggal, Medan.Telp. (061) 804440887 / 80440888 Fax (061) 80440881

PadangJl. Ir Juanda No.22, Kal. Rimbo Kaluang, Kec. Padang Barat.Telp. (0751) 39396Fax (0751) 7052100

PalembangJl. Letjen Hadin No.3853/1867 RT.030, RW 011, Kel. 20 Ilir D-III, Kec. Ilir Timur ITelp. (0711) 314-111, 315-111Fax (0711) 313-004

Bandar LampungJl. Hayam Wuruk No. 45 Kel. Bumi Kedamaian Telp. (0721) 242214, 476458Fax (0721) 263191

PekanbaruJl Pinang No.89, Kel. Wonorejo, Kec. Marpoyam DamaiTelp. (0761) 7474-998Fax (0761) 7874-997

BatamKomplek Accelance Blok B No.22-23 Kel. Teluk Tering, Kec. Batam Centre Telp. 477 578/79Fax. 477576

JambiJl. K.H. Hasyim Azhari No. 4-5, RT.21, RW.05, Kel. Rajawali, Kec. Jambi Timur, Jambi Tlp. 7555891 / 3030943Fax. 7550944

BanjarmasinJl. Pangeran Hidayatullah No.10, RT.015, RW. 001 Telp. (0511) 674-4783 Fax. 0511-326 9711

BalikpapanJl. Indra Kila No.10-A, RT.28 Kel. Balikpapan Utara Telp. (0542) 862-848 Fax. (0542) 721-3016

SamarindaJl. Rapak Indah RT 36, Kal. Karang Asam, Kec. Sungai Kunjang, Samarinda Telp. 0541 274 835Fax. 0541 277 2089

Pon�anakJl. Dr. Wahidin S. No. 88K-88L, Pon�anak Tlp.6588373, 6590031 Fax. 764131

DenpasarJl. Moh. Yamin III No.9, Renon Denpasar Telp. (0361) 4723841, 265033Fax (0361) 265-033

MakassarJl. Andi Mapaodang No. 50, Makassar. Tlp. 855167, 856194 Fax. 855162

TasikmalayaJl. Letkol RE Jaelani, Blok Cikurubuk Ruko, No. 3,RT 01 RW 13, Kel. Mangkibumi, Kec.Linggajaya, Tasikmalaya.Telp. 0265-311 682Fax. 0265-327513

ManadoJl. Maesa No. 9 Ruko nomor 6 dan 7 Lingkungan 7, Kelurahan Ranonunut, Kec. Paal Dua Manado 95129 Telp. 0431 880 4999Fax. 0431 880 8087

Page 11: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

31PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

1 Gudang Pusat1 Central Warehouse

WILAYAH OPERASIONAL PERSEROANWork Areas and Operational Map

32 Kantor Cabang 32 Branch Offices

BanjarmasinDenpasarMakassarManadoBanda AcehMedanPadangPalembangBandar LampungPekanbaruBatamJambi

Jakarta IJakarta IIBekasiTangerang

PurwokertoSemarangYogyakartaSoloSurabayaSidoarjoMalangKediriJemberBalikpapanSamarindaPon�anak

BogorBandungTasikmalayaCirebon

Jakarta

Page 12: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

STRUKTUR ORGANISASI PERSEROAN TAHUN 2018 ORGANIZATION STRUCTURE 2018

Profil Perusahaan Company Profile

03

32 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 13: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

The Board of Commissioners and the Board of Directors regularly review the Company's vision and mission that are constantly developing.

The Board of Commissioners and Directors agree that the Company's vision and mission are s�ll relevant to the condi�ons and objec�ves of the Company. The achievement of Vision and Mission up to 2018 is in accordance with the direc�on of the Company's business ac�vi�es.

Review Visi dan Misi oleh Dewan Komisaris dan Direksi Review of Vision and Mission by the Board of Commissioners and Directors

Vision

To become the most efficient and effec�ve distribu�on company in Indonesia by providing added value to customers and principals.

Mission

To provide the best health care products and services to all regions of Indonesia

Dewan Komisaris dan Direksi secara regular meninjau pernyataan visi dan misi Perusahaan yang senan�asa berkembang.

Dewan Komisaris dan Direksi sepakat bahwa visi dan misi Perusahaan masih relevan dengan kondisi dan tujuan Perusahaan. Pencapaian Visi dan Misi sampai dengan tahun 2018 telah sesuai dengan arah kegiatan usaha Perusahaan.

VISION AND MISION

Visi

Menjadi perusahaan distribusi yang paling efisien dan efek�f di Indonesia dengan memberikan nilai tambah kepada pelanggan dan principal.

Misi

Menyediakan produk pemeliharaan kesehatan dan pelayanan terbaik ke seluruh wilayah nusantara.

VISI DAN MISI

Profil Perusahaan Company Profile

33PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 14: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

03

Izzat bin Othman57 tahun, warga negara Malaysia

Beliau diangkat sebagai Komisaris Utama merangkap Komisaris Independen Perseroan dalam Rapat Umum Pemegang Saham Luar Biasa berdasarkan Akta Pernyataan Keputusan Rapat No. 04 tanggal 9 Juli 2015.

Pendidikan:

1985 : LLB (Hons), University of Malaya

Riwayat Karir

Pada tahun 2006 sampai dengan 2009 beliau bekerja Affin Security Sdn Bhd sebagai Direktur. Tahun 2007 sampai dengan 2009 bekerja di BH Insurance Berhad sebagai Direktur. Tahun 2011 di PT. Millennium Pharmacon lnterna�onal Tbk sebagai Komisaris Independen. Tahun 2015 hingga sekarang sebagai Komisaris Utama dan Komisaris Independen di PT. Millennium Pharmacon lnterna�onal Tbk.

IZZAT BIN OTHMAN

President Commissioner and Independent Commissioner

Komisaris Utama Merangkap Komisaris Independen

Izzat bin Othman57 years old, Malaysian

He was appointed as President Commissioner and Independent Commissioner at the Extraordinary General Mee�ng of Shareholders based on the Deed of Mee�ng Decree No. 04 dated July 9��, 2015

Educa�on

1985 : LLB (Hons), University of Malaya

Work Experience

In 2006 to 2009 he worked Affin Security Sdn Bhd as Director. In 2007 to 2009 he worked at BH Insurance Berhad as Director. In 2011 at PT. Millennium Pharmacon Interna�onal Tbk as Independent Commissioner. From 2015 un�l now as President Commissioner and Independent Commissioner at PT. Millennium Pharmacon Interna�onal Tbk.

DEWAN KOMISARIS BOARD OF COMMISSIONERS

PROFILE DEWAN KOMISARIS Board of Commissioners Profile

34 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 15: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Mohamed Iqbal bin Abdul Rahman 54 tahun, warga negara Malaysia

Beliau diangkat sebagai Komisaris Perseroan dalam Rapat Umum Pemegang Saham Tahunan berdasarkan Akta Pernyataan Keputusan Rapat Nomor 32 tanggal 23 Mei 2012.

Pendidikan:

Beliau memperoleh gelar Bachelor Degree di bidang Computer Science Universitas Putra Malaysia pada tahun 1987.

Riwayat Karir

Beliau bergabung dengan Pharmaniaga pada bulan April 2011 sebagai IT (Informa�on Technology) Director dan kemudian dipromosikan menjadi Chief Opera�ng Officer (COO) pada 1 Juni 2012.

Mohamed Iqbal bin Abdul Rahman

Komisaris Commissioner

Mohamed Iqbal bin Abdul Rahman 54 years old, Malaysian

He was appointed as Commissioner of the Company at the Annual General Mee�ng of Shareholders based on the Deed of Statement of Mee�ng Resolu�ons Number 32 dated May 23��, 2012.

Educa�onHe obtained a Bachelor Degree in Computer Science from Putra University in 1987.

Work Experience

He joined Pharmaniaga in April 2011 as an IT (Informa�on Technology) Director and was promoted to Chief Opera�ng Officer (COO) on June 1��, 2012.

Profil Perusahaan Company Profile

35PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 16: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Norai'ni bin� Mohamed Ali 51 tahun, warga negara Malaysia

Beliau diangkat sebagai Komisaris Perseroan dalam Rapat Umum Pemegang Saham Tahunan berdasarkan Akta Pernyataan Keputusan Rapat Nomor 32 tanggal 23 Mei 2012.

Pendidikan:

Beliau memperoleh gelar Sarjana Akuntansi (Kehormatan) Akuntansi dan Keuangan dari Liverpool John Moores University, Inggris pada tahun 1990 dan merupakan anggota dari Associa�on of Chartered Cer�fied Accountants.

Riwayat Karir

Sebelum bergabung dengan Pharmaniaga pada tahun 2001, Norai'ni bergabung dengan Opus Group Berhad, anak perusahaan dari UEM Group Berhad selama 8 tahun. Dia adalah Manajer Umum Senior sebelum kenaikan pangkatnya sebagai Direktur Pengadaan pada tahun 2011. Selanjutnya dia ditunjuk sebagai Chief Financial Officer Grup Pharmaniaga pada tahun 2012. Selain menjadi Komisaris Perusahaan, saat ini dia juga duduk di Dewan Anak Perusahaan Grup Pharmaniaga lokal dan luar negeri. Dia bertanggung jawab untuk semua masalah keuangan termasuk akuisisi bisnis strategis, perbendaharaan dan strategi manajemen risiko Grup Pharmaniaga.

Norai'ni binti Mohamed Ali Komisaris

Commissioner

i Norai'ni bin� Mohamed Al 51 years old, Malaysian

She was appointed as Commissioner of the Company at the Annual General Mee�ng of Shareholders based on the Deed of Statement of Mee�ng Resolu�ons Number 32 dated May 23��, 2012.

Educa�on

She obtained her Bachelor of Arts (Honours) Accoun�ng and Finance from Liverpool John Moores University, United Kingdom in 1990 and is a member of Associa�on of Chartered Cer�fied Accountants (ACCA).

Work Experience

Prior to joining Pharmaniaga in 2001, Norai’ni was attached to Opus Group Berhad, a subsidiary of UEM Group Berhad for 8 years. She was a Senior General Manager preceding to her promotion as Procurement Director in 2011. Subsequently she was appointed as the Pharmaniaga Group Chief Financial Officer in 2012. Aside from being a Commissioner of the Company, currently she also sits on the local Board of subsidiaries of Pharmaniaga Group and overseas. She is responsible for all financial issues including the acquisition of strategic business, treasury and risk management strategies of the Pharmaniaga Group.

Profil Perusahaan Company Profile

03

36 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 17: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

dr. Nyoman Kumara Rai75 tahun, warga Negara Indonesia

Beliau diangkat sebagai Komisaris dan Komisaris Independen Perseroan berdasarkan Akta Berita Acara Rapat Umum Pemegang Saham Luar Biasa No. 4 pada tanggal 21 Oktober 2014.

Pendidikan:

Beliau menyelesaikan studinya di Fakultas Kedokteran, Universitas Indonesia, dengan penghargaan pada tahun 1968. Kemudian pada tahun 1971 menyelesaikan pendidikan di London School of Hygiene and Tropical Medicine, London. Pada tahun 1976, beliau mendapatkan gelar Master in Public Health, MPH, jurusan perencanaan kesehatan dengan penekanan pada pembangunan sosial ekonomi pada School of Public Health, University of Michigan, Michigan, Amerika Serikat.

Riwayat Karir

Beliau memulai karirnya di Departemen Kesehatan dari tahun 1968 sampai dengan 1988 sebagai staf pada Direktorat Jenderal Pencegahan, Pemberantasan dan Pembasmian Penyakit Menular (Ditjen P4M). Dimulai dengan program Pembasmian Penyakit Cacar (Smallpox Eradica�on Program) kemudian Kepala Sub-Direktorat Imunisasi , Kepala Bagian Perencanaan, Kepala Sub-Dit Pemberantasan Malaria dan Direktur untuk Pemberantasan Penyakit yang Menular Langsung dan terakhir sebagai Sekretaris Ditjen Pemberantasan Penyakit Menular dan Kesehatan Lingkungan. Pada tahun 1988 hingga 1995 sebagai Kepala Biro Perencanaan Departemen Kesehatan. Dari 1995 hingga 1998 sebagai Dirjen Pembinaan Kesehatan Masyarakat. Dari tahun 1998 hingga 1999 sebagai Penasehat Senior Menteri Kesehatan untuk bidang pembiayaan kesehatan dan peran serta masyarakat.

Setelah pensiun dini dar i Departemen Kesehatan, beliau berkarir di Badan Kesehatan Dunia (WHO-World Health Organiza�on) untuk kantor regional Asia Tenggara di New Delhi (World Health Organiza�on-South East Asia Regional Office). Dimulai tahun 1999 hingga

dr. Nyoman Kumara Rai

Komisaris merangkap Komisaris Independen Commissioner and Independent Commissioner

dr. Nyoman Kumara Rai75 years old, Indonesian

He was appointed as Commissioner and Independent Commissioner of the Company based on the Deed of Minutes of Extraordinary General Mee�ng of Shareholders No. 4 on October 21��, 2014.

Educa�on

He graduated with dis�nc�on from Faculty of Medicine, University of Indonesia in 1968. In 1971 he finished his post-graduate study at London School of Hygiene and Tropical Medicine in London. In 1976 he obtained his Master of Public Health in health planning with emphasis on socio economic development in School of Public Health, University of Michigan, Michigan, United States of America (USA).

Work Experience

He started his career in Ministry of Health from in 1968 to 1988 as staff of Directorate General-Control of Communicable Diseases, star�ng with Smallpox Eradica�on Programme, Chief Sub-directorate of Immuniza�on, Chief Planning Unit, Chief Sub-directorate of Malaria Control and Director Diseases with Direct Transmission and finally Secretary Directorate General-Control of Communicable Diseases and Environmental Health. From 1988 to 1995 as Director Bureau of Planning Ministry of Health. In 1995 he was promoted as Director General Community Health and served this post �ll 1998. From 1998 to 1999 he served as Senior Advisor to Minister of Health in Community Par�cipa�on and Health Care Financing.

A�er an early re�rement in 1999, he immediately joined WHO-World Health Organiza�on-South East Asia Regional Office in New Delhi star�ng as Director Health Systems and Community Health and in 2001 as Director Communicable Disease. From March to October 2004 he was assigned as

37PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 18: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Informasi Rangkap Jabatan Dewan KomisarisInformation on Multiple Positions of the Board of Commissioners

Posisi di PerseroanPosition in PT. MPI Tbk

NamaName

No.

1. Norai'ni bin�Mohamed Ali

Chief Financial Officer di Pharmaniaga Berhad

Chief Financial Officer in Pharmaniaga Berhad

Posisi di Perusahaan lain

Komisaris

Commissioners

2. Mohamed Iqbal binAbdul Rahman

Chief Operating Officer di Pharmaniaga Berhad

Chief Operating Officer in Pharmaniaga Berhad

Komisaris

Commissioners

2005 sebagai Director Health Systems and Community Health dan terakhir sebagai Director Communicable Diseases. Selama bulan Maret hingga Oktober 2004 menjadi pejabat Kepala Perwakilan WHO di Thailand. Bulan Maret 2005 beliau pensiun dari WHO. Dari tahun 2006 hingga 2008 WHO mengangkat kembali sebagai Temporary Interna�onal Professional untuk pemberantasan penyakit menular pada perwakilan WHO untuk Indonesia. Pada tahun 2008 beliau diminta untuk membantu lagi Kantor Regional WHO wilayah Asia Tenggara hingga 2009 sebagai Director Health Systems Development. Dari Juni 2009 diangkat menjadi Penasehat Direktur Regional WHO sampai dengan Oktober 2013.

Beliau juga menjadi konsultan jangka pendek (short term consultant) pada Assessment of Malaria Eradicaeon di Srilanka pada Maret 1984 kemudian di bulan November 1979 pada Smallpox Eradicaeon Program di Afganistan dan Pakistan serta pada bulan Oktober hingga Desember 1972 pada Smallpox Eradicaeon Program di Bhar, India.

Ac�ng WHO Representa�ve to Thailand. In 2005 he re�red from WHO, but in 2006 he was asked to rejoin as Temporary Interna�onal Professional on Communicable Diseases, at WHO Country office Indonesia. In 2008 he was reassigned to WHO South-East Asia Regional Office as Director Health Systems Development �ll 2009. In 2009 he served as Advisor to the Regional Director �ll October 2013.

He was also a short term consultant on Assessment of Malaria Eradica�on in Sri lanka in March 1984 and on Assessment of Smallpox Eradica�on Programme in Afghanistan and Pakistan in November 1979, and finally on Smallpox Eradica�on in Bhar, India in October-December 1972.

Seluruh anggota Dewan Komisaris Perseroan �dak memiliki hubungan keuangan atau hubungan keluarga dengan anggota Dewan Komisaris, Direksi lainnya dan/atau Pemegang Saham Pengendali.

All members of the Company's Commissioners do not hold concurrent posi�ons, either as members of the Board of Directors, members of the Board of Commissioners, and/or commi�ee members and other posi�ons in other companies or ins�tu�ons.

Independensi Anggota Dewan KomisarisIndependence of Board of Commissioners Members

Profil Perusahaan Company Profile

03

38

Position at other Company

PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 19: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Informasi untuk Pelatihan Dewan Komisaris Tahun 2018 Information for Board of Commissioners Training in 2018

Pelatihan KomisarisCommissioners Training

TanggalDate

PelatihanName of training

JabatanDesignation

NamaName

Izzat bin Othman Komisaris Utama dan Komisaris Independen

President Commissioner

and Independent Commissioner

Komisaris Independen

Independent Commissioner

Audit Commi�ee Ins�tute (ACI) Breakfast Roundtable 2018

3 Agustus 2018 August 3��, 2018

Mohamed Iqbal bin Abdur Rahman

Komisaris

Comissioner

Komisaris

Comissioner

Norai'ni bin� Mohamed Ali

1. Malaysian Leadership Summit 2018:Leadership in the Age of Disrup�on

2. Awareness On Iso 37001:2016, An�-Bribery Management System (Abms)Requirements

1. Strategic Finance For Decision Makers

2. Decoding Transac�on and Rpt Rules

8 Mei 2018May 8��, 2018

28 Agustus 2018 August 28��, 2018

16 sampai 17 Juli 2018 July 16�� to 17��, 2018

5 sampai 6 September 2018 September 5�� to 6��, 2018

dr. Nyoman Kumara Rai NoneNone

Profil Perusahaan Company Profile

39PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 20: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

DEWAN DIREKSIBOARD OF DIRECTORS

PROFILE DEWAN DIREKSI Board of Directors Profile

Mohamad Muhazni bin Mukhtar 50 tahun, warga negara Malaysia

Beliau diangkat sebagai Presiden Direktur Perseroan pada Rapat Umum Pemegang Saham Luar Biasa berdasarkan Akta No. 4, tertanggal 18 Oktober 2012.

Pendidikan:

Beliau memiliki gelar Associate Amerika dari Universitas Indiana pada tahun 1988, gelar BBA dalam bidang Ilmu Manajemen dari Universitas Iowa pada tahun 1990, gelar MBA dari Universitas Ohio / Ins�tut Teknologi MARA pada tahun 1993 dan gelar Master of Science dalam Kepemimpinan Bisnis dari Newcastle Business School, Universitas Northumbria pada tahun 2010

Riwayat Karir

Beliau memulai karirnya sebagai Marke�ng Execu�ve di London & Pacific Insurance Bhd pada 1991. Dari 1993 hingga 1996, ia bekerja di Plus Expressway Bhd, dengan posisi terakhir di sana sebagai Senior Management Executieve Corporate Finance. Dari 1996 hingga 2009, ia bekerja di Touch 'n Go Sdn Bhd dengan posisi terakhir di sana sebagai General Manager-Operations dan Project Management. Pada 2009, beliau bergabung dengan Faber Group Bhd sebagai General Manager Corporate Services. Pada 2011, beliau terikat pada Faber Facilities Sdn Bhd sebagai Chief Operating Officer dan terlibat dalam investasi Faber di United Emirat Arab dan India. Beliau diangkat sebagai Presiden Direktur Perusahaan pada tahun 2012. Beliau juga adalah Sekretaris Kehormatan Kamar Malaysia di Jakarta untuk periode 2015 hingga 2019.

MOHAMAD MUHAZNI BIN MUKHTAR

DIREKTUR UTAMAPRESIDENT DIRECTOR

Mohamad Muhazni bin Mukhtar 50 years old, Malaysian

He was appointed as President Director of the Company at the Extraordinary General Mee�ng of Shareholder based on the Deed Number 4, dated 18�� October 2012.

Educa�on

He possesses an American Associate Degree from Indiana University in 1988, a BBA in Management Science from the University of Iowa in 1990, an MBA from Ohio University/ MARA Ins�tute of Technology in 1993 and a Master of Science in Business Leadership from Newcastle Business School, Northumbria University in 2010.

Work Experience

He started his career as a Marke�ng Execu�ve at London & Pacific Insurance Bhd in 1991. From 1993 to 1996, he worked at Plus Expressway Bhd, with his last posi�on there as a Corporate Finance Senior Management Execu�ve. From 1996 to 2009, he worked at Touch 'n Go Sdn Bhd with his last posi�on there as a General Manager Opera�ons and Project Management. In 2009, he joined Faber Group Bhd as a General Manager of Corporate Services. In 2011, he was a�ached to Faber Facili�es Sdn Bhd as Chief Opera�ng Officer and was involved in Faber's investments in United Arab Emirates and India. He was appointed as the Company's President Director in 2012. He is also the Honorary Secretary of Malaysia Chambers of Jakarta for the period of 2015 to 2019.

Profil Perusahaan Company Profile

03

40 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 21: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Ahmad Abu Bakar49 tahun, warga negara Malaysia

Beliau yang diangkat sebagai Direktur Perseroan dalam Rapat Umum Pemegang Saham Luar Biasa berdasarkan Akta Pernyataan Keputusan Rapat Nomor 49 tanggal 29 September 2011.

Pendidikan:

Bachelor of Pharmacy dari Bradford University, England pada tahun 1993

Riwayat Karir

Beliau mengawali sabagai Pre-registration Pharmacist Bradford Royal Infirmary, Bradford, England pada tahun 1990. Kemudian pada tahun 1992 bekerja di Lipha Pharmaceuacals, Hitchin, England sebagai Pre-registration Pharmacist. Tahun 1994 bekerja di Guardian Pharmacy, Bangsar Shopping Complex, Kuala Lumpur, Malaysia sebagai Retail Pharmacist. Pada tahun 1995 bekerja di SMP Pharmaceuticals Sdn Bhd, Sungai Petani, Kedah, Malaysia sebagai Quality Assurance (QA) Manager. Pada tahun 1998 bekerja di Mico Pharmacy Sdn Bhd, Alor Setar, Kedah, Malaysia sebagai Pharmacy Manager. Pada tahun 2000 bekerja di KPJ Bukit Mertajam Specialist Hospital, Penang, Malaysia sebagai Manajer. Pada tahun 2004 bekerja di Pharmaniaga Logistics Sdn Bhd, Penang, Malaysia sebagai Deputy Senior Manager. Pada tahun 2011 hingga sekarang bekerja di PT. Millennium Pharmacon Interna�onal Tbk, Jakarta, Indonesia sebagai Direktur.

AHMAD BIN ABU BAKAR DIREKTUR DIRECTOR

Ahmad Abu Bakar 49 years old , Malaysian

He was appointed as Director of the Company at the Extraord inary Genera l Mee�ng of Shareholders based on the Deed of Statement of Mee�ng Resolu�ons Number 49 dated 29�� September 2011.

Educa�on

Bachelor of Pharmacy from Bradford University, England in 1993

Work Experience

He started as Pre-registra�on pharmacist of Bradford Royal Infirmary Pharmacist, Bradford, England in 1990. In 1992 worked at Lipha Pharmaceu�cals, Hitchin, England as a Pre-registra�on Pharmacist. In 1994 he worked at Guardian Pharmacy, Bangsar Shopping Complex, Kuala Lumpur, Malaysia as a Retail Pharmacist. In 1995 he worked at SMP Pharmaceu�cals Sdn Bhd, Sungai Petani, Kedah, Malaysia as a Quality Assurance Manager (QA). In 1998 he worked at Mico Pharmacy Sdn Bhd, Alor Setar, Kedah, Malaysia as Pharmacy Manager. In 2000 he worked at KPJ Bukit Mertajam Specialist Hospital, Penang, Malaysia as a Manager. In 2004 he worked at Pharmaniaga Logis�cs Sdn Bhd, Penang, Malaysia as Deputy Senior Manager. In 2011 un�l now he is working at PT. Millennium Pharmacon Interna�onal Tbk, Jakarta, Indonesia as Director.

Profil Perusahaan Company Profile

41PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 22: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

IVAN HANAFI58 tahun, warga negara Indonesia

Beliau diangkat sebagai Direktur Perseroan berdasarkan Akta Pernyataan Keputusan Rapat Nomor 35 tanggal 6 April 2018 yang ditetapkan dalam Rapat Umum Pemegang Saham Tahunan.

Pendidikan:

Beliau menerima gelar B.Sc. dalam Pendidikan Elektronik dari Universitas Negeri Jakarta (sebelumnya IKIP Jakarta) pada tahun 1986, Magister Pendidikan (M.Ed.) dalam Pendidikan Teknis dan Kejuruan dari Universitas Negeri Yogyakarta (sebelumnya IKIP Yogyakarta) pada tahun 1996, dan B.Eng. di bidang Teknik Elektronika dari Universitas Indonesia pada tahun 2000. Dia mendapat gelar Ph.D. dalam Pendidikan Teknis dan Kejuruan dari Universi� Putra Malaysia (UPM) pada tahun 2007.

Riwayat Karir

Beliau telah bekerja sebagai Koordinator Pela�han untuk Pusat Pela�han Teknis, Perusahaan Siemens Indonesia (tahun 1994 sampai dengan 1995), kemudian sebagai Konsultan ke Departemen Pendidikan Nasional, membantu Terro-Technologist International Konsultan untuk meninjau pemeliharaan prevenaf dan program manajemen berbasis sekolah yang digunakan dalam Pendidikan Menengah dan Tinggi (tahun 1997 sampai dengan 2002), sebagai Ketua Komite beasiswa doktoral dan pela�han jangka pendek di luar negeri pada program BERMUTU, Direktorat Jenderal Pendidikan Tinggi, Departemen Pendidikan dan Budaya (tahun 2008 sampai dengan 2010), Koordinator Proyek Peneli�an dan Jejaring Pendidikan Kejuruan dan Teknis Asia Tenggara untuk Indonesia (tahun 2009 sampai dengan 2010), Kepala Pusat Studi Kebijakan Pendidikan, Universitas Negeri Jakarta (tahun 2011 sampai dengan 2014), dan Ketua Program Magister Pendidikan Teknis dan Kejuruan, Universitas Negeri Jakarta (tahun 2013 sampai dengan 2017).

IVAN HANAFI Direktur Independen Independent Director

IVAN HANAFI58 years old, Indonesian

He was appointed as Director of the Company pursuant to Deed of Statement of Mee�ng Resolu�ons Number 35 dated April 6��, 2018 which was determined at the Annual General Mee�ng of Shareholders.

Educa�on

He receives his B.Sc. in Electronic Educa�on from Universitas Negeri Jakarta (former IKIP Jakarta) in 1986, Master of Educa�on (M.Ed.) in Technical and Voca�onal Educa�on from Universitas Negeri Yogyakarta (former IKIP Yogyakarta) in 1996, and B.Eng. in Electronics Engineering from Universitas Indonesia in 2000. He has got Ph.D. in Technical and Voca�onal Educa�on from Universi� Putra Malaysia (UPM) in 2007.

Work Experience

He has been conducted as Training Coordinator for Technical Training Center, Siemens Indonesia Company (in 1994 to 1995), Consultant to The Ministry of Na�onal Educa�on, assisted the Terro-Technologist Interna�onal Consultant to review preven�ve maintenance and school-based management programs used in Junior and Senior Secondary Educa�on (in 1997 to 2002), Chairman of the commitee for doctoral scholarship and short-term training abroad on BERMUTU program, Directorate General of Higher Educa�on, Ministry of Educa�on and Culture (in 2008 to 2010), Coordinator of the South East Asian Voca�onal and Technical Educa�on Research and Networking (SEAVERN) Project for Indonesia (in 2009 to 2010), Head of Center for Educa�onal Policy Studies, Universitas Negeri Jakarta (in 2011 to 2014), and Chairperson of Master Programme for Technical and Voca�onal Educa�on, Universitas Negeri Jakarta (in 2013 to 2017).

Profil Perusahaan Company Profile

03

42 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 23: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Profil Perusahaan Company Profile

Seluruh anggota Direksi Perseroan �dak memiliki hubungan keuangan atau hubungan keluarga dengan anggota Dewan Komisaris, Direksi lainnya dan/atau Pemegang Saham Pengendali.

All members of the Board of Directors of the Company do not have a financial rela�onship or family rela�onship with other members of the Board of Commissioners, Directors and / or Controlling Shareholders.

Independensi Anggota DireksiIndependence of Directors

Seluruh anggota Direksi Perseroan �dak merangkap jabatan rangkap jabatan, baik sebagai anggota Direksi, anggota Dewan Komisaris, dan/atau anggota komite serta jabatan lainnya di perusahaan atau lembaga lain.

All members of the Company's directors do not hold concurrent posi�ons, either as members of the Board of Directors, members of the Board of Commissioners, and / or commi�ee members and other posi�ons in other companies or ins�tu�ons.

Informasi Rangkap Jabatan DireksiInformation on Multiple Position of Directors

Informasi untuk Pelatihan Direksi Tahun 2018 Information for Directors Training in 2018

Pelatihan Direksi Tahun 2018 Directors Training in 2018

TanggalDate

PelatihanName of training

JabatanDesignation

NamaName

Mohamad Muhazni bin Mukhtar

Direktur Utama

President Director

Penyelenggara: GP Farmasi IndonesiaOrganizer: Indonesian Pharmacy GP

Tema : Peran Regulator dalam Menghadapi Era Digitalisasi 4.0 di Industri Kesehatan Indonesia

Theme: Role of Regulators in Facing the Age of Digital iza�on 4.0 in Indonesia's Health Industry

4 Desember 2018

December 4��, 2018

Ahmad binAbu Bakar

Direktur

DirectorNoneNone

Ivan Hanafi Direktur Independen

Independent Director

NoneNone

43PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 24: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

03

Profil Perusahaan Company Profile

Perseroan menyadari bahwa keberhasilan kegiatan usahanya tergantung pada kemampuan Perseroan dalam merekrut talenta terbaik di pasar tenaga kerja, serta kemampuannya dalam mengembangkan , Memotivasi dan mempertahankan sumber daya manusianya. Pengembangan usaha Perseroan, baik secara organik maupun melalui proses merger & akuisisi, juga menciptakan berbagai peluang dan tantangan bagi Perseroan dalam mengelola sumberdaya manusia dan organisasinya. Oleh karena itu, Perseroan terus mengembangkan Sumber Daya Manusia serta meningkatkan aspek hubungan industrial dengan karyawan. Melihat potensi masa depan Indonesia sebagai salah satu wilayah dengan pertumbuhan pasar terkuat di regional, Perseroan berkomitmen melakukan investasi signifikan pada sumber daya manusia se�ap kali diperlukan.

MPI realizes that the success of its business opera�on rests upon the Company's ability in a�rac�ng the best talents in the market, as well as its capabili�es in developing, mo�va�ng and retaining its people. The Company's business expansion, both through organic approach and mergers & acquisi�ons, also present considerable opportuni�es and challenges for the Company in managing its human capital and organiza�on. MPI therefore con�nues to develop its Human Resources, while also enhancing industrial rela�ons aspects with employees. In recognizing the poten�al of Indonesia as one of the strongest growing markets in the region, the Company has a commitment to make significant investman in the country's human resources, whenever necessary.

KOMPOSISI KARYAWAN DAN DESKRIPSI PENGEMBANGAN KOMPETENSI Composition of the Employees and Description of Competency Development

SDM ditujukan untuk menjadi mitra strategis bagi sektor usaha Perseroan dan semua fungsi grup, menjalankan pertumbuhan bisnis dan transformasi, menggerakan efisiensi organisasi, meningkatkan kepemimpinan, bakat, dan kinerja, serta membangun dan memelihara budaya Perseroan TOPIC “Teamwork, Open communica�on, Passion, Integrity, Caring”.

Di Perseroan, SDM perseroan diiden�fikasikan sebagai satu dari kunci strategi bisnis dengan prioritas utama:

§ Pemberdayaan Pemimpin: setiap pemimpin diMPI aktif dan terpercaya dalam pengambilankeputusan berdasarkan informasi yangtransparan.

§ Keterlibatan Manusia: menekankan bahwakaryawan bekerja di lingkungan yang beragamdan dalam satu �m.

§ Kecakapan Bakat: mendorong pembangunanberkelanjutan bagi semua karyawan MPI.

Strategi SDMHuman Resources Strategy

HR is aiming to be a strategic partner for the Company's business sectors and all group func�ons in terms of enabling business growth and transforma�on, driving organiza�onal efficiency, enhancing leadership, talent and performance, as well as building and fostering the Company's corporate culture TOPIC “Teamwork, Open communica�on, Passion, Integrity, Caring”.

At the Company, people are iden�fied as one of business strategy by priori�zing core topics:

§ Empowered Leaders: every leader at MPI isenabled (and trusted) to make decisionsbased on transparent informa�on.

§ Engaged People: emphasizes that we work ina more diverse environment and team.

§ Capable Talents: fostering con�nuousdevelopment for all employees at MPI

44 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 25: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Per 31 Desember 2018, jumlah karyawan Perseroan mencapai 1087 orang, dari 1027 karyawan pada 31 desember 2017, profil karyawan kami per 31 Desember 2018 adalah sebagai berikut:

As of Desember 31st, 2018, the Company employed 1087 employees, compared to 1027 employees as December 31st, 2017. Our employee profile as of December 31st, 2018 is as follows:

Profil KaryawanEmployee Profil

Seluruh anggota direksi Perseroan �dak merangkap jabatan, baik sebagai anggota Direksi, anggota Dewan Komisaris, dan/atau anggota komite serta jabatan lainnya di perusahaan atau lembaga lain.

All members of the Company's directors do not hold concurrent posi�ons, either as members of the Board of Directors, members of the Board of Commissioners, and/or commi�ee members and other posi�ons in other companies or ins�tu�ons.

Komposisi Karyawan Berdasarkan Tingkat Pendidikan Composition of Employees by Education

Jumlah / Total

SD & SLTP / Elementary & Middle School

Pendidikan / Educa�on

17

SMA / High School

140DIPLOMA

658

STRATA 1 / Undergraduate 268

S2 / Post Graduate 4

Komposisi Karyawan Berdasarkan JabatanComposition of Employees by Position

Jumlah / Total

Others Staff

Jabatan / Job Posi�on

498

Staff

155Supervisor

366

Manager 68

Komposisi Karyawan Berdasarkan Jenis Kelamin Composition of Employees by Gender

Jenis Kelamin / Gender

Perempuan / Female 228

Laki-laki / Male 859

Jumlah / Total

Profil Perusahaan Company Profile

45PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 26: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Komposisi Karyawan Berdasarkan Usia Composition of Employees by Age

18 - 25 tahun

Jenis Kelamin

Gender

Wanita / Woman

87Pria / Male

43

Usia / Age

26 - 35 tahun 36 - 45 tahun 46 - 55 tahun > 55 tahun

375

108

262

55

127

22

7

1

MPI menyediakan instrumen yang efek�f untuk mendukung pengembangan dan pembelajaran karyawan. Rencana pengembangan in i didefinisikan sebagai pengembangan kebutuhan yang spesifik dimana karyawan harus bekerja dengan baik di posisi mereka saat ini dan/atau untuk mempersiapkan diri demi tantangan di masa depan. Sementara i tu, Div is i HR memberikan proses dan alat yang sesuai, seper� tawaran dukungan yang diperlukan untuk menciptakan kinerja tenaga kerja yang �nggi.

Se�ap karyawan di Perseroan memiliki hak untuk mendapatkan pengembangan karir sesuai tingkat pendidikan mereka . Perseroan juga menyediakan berbagai jenis pela�han baik umum maupun in-house.

Di bawah ini adalah beberapa pela�han yang diselenggarakan sepanjang tahun 2018:

MPI provides an effec�ve instrument to support development and learning for employees. Specifically, the development requires the employees to work hard and to be able to perform well in their current posi�on and/or to prepare themselves for future challenges. Meanwhile, the HR Division provides the relevant processes and tools, as well as offering support needed to build a high performance workforce.

Each employee in the Company has the right to obtain career development in accordance to their level of educa�on. MPI also provides various types of training both public and inhouse (local and overseas).

Below are some trainings which helds during year 2018:

Program Pengembangan Development Program

Waktu & Tempat Pelaksanaan

Time and Place of the Ac�vity

The 4 Disciplines of Execu�on (season 2)

Program Pengembangan Karyawan

Employee Development Program

9th Indonesia Customer Experience Management

The 7 Habits of Highly Effec�ve People Training

Communica�on Skill

Training Stock Supervisor

16 Januari 2018, Malang

11 hingga 12 Juli 2018, Jakarta

15 hingga 16 Agustus 2018, Jakarta

7 September 2018, Jakarta

4 hingga 5 Desember 2018, Jakarta

03

Profil Perusahaan Company Profile

46 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 27: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

KOMPOSISI PEMEGANG SAHAMComposition of Shareholders

Nama pemegang saham dan persentase kepemilikan Per tanggal 31 Desember 2018

Shareholders of the Company and Ownership Percentage As per December 31��, 2018

Pemegang Saham

Shareholders

Pharmaniaga Interna�onal

Corpora�on Sdn Bhd

Inst. asing

Malaysia935.541.534 74,43%

Persentase Kepemilikan Saham

Percentage of Share Ownership

Saham Ditempatkan dan Disetor Penuh

Shares Issued and Fully Paid

Group Status

Group Status

PT Danpac Pharma Inst. Lokal

IND

173.744.820 13,64%

PT Indolife Pensiontama

Inst. Lokal

IND

42.762.830 3,36%

PT Ngrumat Bondo Utomo

Inst. Lokal

IND

23.731.000 1,86%

Masyarakat

The PublicIND 98.219.816 7,71%

JUMLAH

TOTAL1.274.000.000 100%

Sumber:

1. PT Sirca Datapro Perdana 2. PT Kustodian Sentral Efek Indonesia

References:

1. PT Sirca Datapro Perdana2. PT Kustodian Sentral Efek Indonesia

Kepemilikan Saham oleh Dewan Komisaris dan Direksi Share Ownership by the Board of Commissioners and Board of Directors

Dewan Komisaris dan Direksi �dak memiliki kepemilikan saham di Perseroan

The Board of Commissioners and Directors do not have share ownership in the Company

Profil Perusahaan Company Profile

47PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 28: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

KRONOLOGI PENERBITAN SAHAM Chronology of the Company Stock Listing

Berdasarkan persetujuan Menteri Keuangan Republlik Indonesia dengan Surat Keputusan No. SI-090/SHM/MK.10/1990 tanggal 22 Maret 1990 Perseroan menjual sebagian sahamnya kepada masyarakat, dan pada tanggal 7 Mei 1990 telah dicatatkan pada Bursa Efek Jakarta dan Bursa Efek Surabaya saham sebanyak 3.500.000 lembar dengan nilai nominal Rp 1.000 per saham yang merupakan 38,46% dari modal saham yang ditempatkan dan disetor penuh.

Pada tanggal 12 Januari 1994 Perseroan mencatatkan sahamnya yang berasal dari saham bonus sejumlah 4.550.000 lembar di Bursa Efek Jakarta dan Bursa Efek Surabaya. Kemudian pada tanggal 16 Desember 1994 Perseroan mencatatkan sahamnya yang berasal dari saham pendiri 5.600.000 lembar.

Pada tanggal 2 Februari 1999 Perseroan melaksanakan pemecahan saham (stock split) sehingga saham yang dicatatkan di Bursa Efek Jakarta dan Bursa Efek Surabaya menjadi 27.300.000 lembar dengan nominal Rp 500.

Pada tanggal 24 Februari 1999 Perseroan melaksanakan pembagian saham bonus dengan jumlah saham sebanyak 4.550.000 lembar yang kemudian dicatat di Bursa Efek Jakarta tanggal 25 Februari 1999 dan di Bursa Efek Surabaya pada tanggal 24 Februari 1999.

Disusul kemudian pada tanggal 16 Juni 1999 pembagian saham bonus kedua dengan jumlah saham sebanyak 4.550.000 lembar yang juga telah dicatat di Bursa Efek Jakata tanggal 17 Juni 1999 dan di Bursa Efek Surabaya pada tanggal 16 Juni 1999.

Sehingga total saham yang dicatat di Bursa Efek Jakarta dan Bursa Efek Surabaya sebanyak 36.400.000 lembar saham dengan nilai nominal Rp 500 per saham.

Based on the approval of the Minister of Finance of the Republic of Indonesia with its Decree No. SI-090/SHM/MK.10/1990 dated March 22nd, 1990, the Company sold some of its shares to the public, and in May 7th, 1990 it has listed 3,500,000 shares in the Jakarta Stock Exchange and Surabaya Stock Exchange, with nominal value of Rp 1,000 per share which cons�tute 38.46% from the subscribed and fully paid-up share capital.

In February 17th, 1994 the Company has listed its shares from the bonus issue totaling 4,550,000 shares at the Jakarta Stock Exchange and Surabaya Stock Exchange. Therea�er, in December 16th, 1994 the Company listed the shares originated from the subscriber shares totaling 5,600,000.

In February 2nd, 1999 the Company conducted a stock split exercise resulted to the total shares listed at the Jakarta Stock Exchange and Surabaya Stock Exchange became 27,300,000 shares with a nominal value of Rp 500.

In February 24th, 1999, the Company conducted a distribu�on of bonus shares with a total of 4,550,000 shares which were then listed at the Jakarta Stock Exchange in February 25th, 1999 and at the Surabaya Stock Exchange in February 24th, 1999.

Then followed by in June 16th, 1999, the second distribu�on of bonus shares with a total of 4,550,000 shares which were also listed at the Jakarta Stock Exchange in June 17th, 1999 and at the Surabaya Stock Exchange in June 16th, 1999.

Thus total shares listed at the Jakarta Stock Exchange and Surabaya Stock Exchange were 36,400,000 shares with nominal value of Rp 500 per share.

03

Profil Perusahaan Company Profile

48 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 29: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Dengan persetujuan Badan Pengawas Pasar Modal (Bapepam) melalui suratnya No. S-1345/PM/2000 tanggal 7 Juni 2000, Perseroan melaksanakan Penawaran Umum Terbatas (PUT) I dengan terlebih dahulu melaksanakan Hak Memesan Efek Terlebih Dahulu (HMETD) atas sejumlah sebanyak-banyaknya 72.800.000 saham sehingga jumlah saham meningkat menjadi 109.200.000 lembar dengan nilai nominal Rp 500, dan telah dicatat di Bursa Efek Jakarta dan Bursa Efek Surabaya pada tanggal 4 Juli 2000.

Sebagaimana termaktub dalam Akta Notaris No. 42 tanggal 28 Mei 2001, Perseroan melaksanakan pemecahan saham (stock split) dari semula bernilai nominal Rp 500 se�ap saham menjadi Rp 100 se�ap saham dengan jumlah saham meningkat menjadi sebanyak 546.000.000 lembar, dan telah dicatat di Bursa Efek Jakarta dan Bursa Efek Surabaya pada tanggal 3 September 2001.

Dengan persetujuan Badan Pengawas Pasar Modal (Bapepam) melalui suratnya No. S-1362/PM/2002 tanggal 21 Juni 2002, Perseroan melaksanakan Penawaran Umum Terbatas (PUT) II dengan menerbitkan Hak Memesan Efek Terlebih Dahulu (HMETD) untuk sejumlah 182.000.000 saham dan jumlah saham menjadi 728.000.000 lembar dengan nilai nominal Rp 100. Sejumlah saham tersebut telah dicatatkan di Bursa Efek Jakarta dan Bursa Efek Surabaya pada tanggal 17 Juli 2002.

Dengan persetujuan Otoritas Jasa Keuangan (OJK) melalui suratnya No. S-443/D.04/2017 tanggal 17 November 2017, Perseroan melaksanakan Penawaran Umum Terbatas (PUT) III dengan menerbitkan Hak Memesan Efek Terlebih Dahulu (HMETD) untuk sejumlah 546.000.000 saham baru dan jumlah saham menjadi 1.274.000.000 lembar dengan nilai nominal Rp 100. Sejumlah saham tersebut telah dicatatkan di Bursa Efek Indonesia pada tanggal 15 Desember 2017.

With approval from the Capital Market Supervisory Board (Bapepam) through its le�er No. S-1345/PM/2000 dated June 7th, 2000, the Company conducted a Limited General Offer (Right Issue Exercise) I by firstly conduc�ng the Right to Order Stock Preemp�vely (HMETD) for a maximum amount of 72,800,000 shares so that total shares increased to 109,200,000 shares with nominal value of Rp 500 and were listed at the Jakarta Stock Exchange and Surabaya Stock Exchange in July 4th, 2000.

As stated in the Notary Deed No. 42 dated May 28th, 2001, the Company has conducted a stock split from a nominal value of Rp 500 for each share to become Rp 100 for each share with total shares increased to 546,000,000 shares, and were listed at the Jakarta Stock Exchange and Surabaya Stock Exchange in September 3rd, 2001.

With the approval from the Capital Market Supervisory Board (Bapepam) through its le�er No. S-1362/PM/2002 dated June 21st, 2002, the Company conducted a Limited General Offer (PUT) II by issuing the Right to Order Stock Preemp�vely (HMETD) for 182,000,000 shares and total shares increased to 728,000,000 shares with a nominal value of Rp 100. The shares were listed at the Jakarta Stock Exchange and Surabaya Stock Exchange in July 17th, 2002.

With the approval from the Otoritas Jasa Keuangan (OJK) through its le�er No. S- No. S-443/D.04/2017 dated 17th November 2017, the Company conducted a Limited General Offer (PUT) III by issuing the Right to Order Stock Preemp�vely (HMETD) for 546,000,000 shares and total shares increased to 1.274.000.000 shares with a nominal value of Rp 100. The shares were listed at the Indonesia Stock Exchange in 15�� December 2017.

Profil Perusahaan Company Profile

49PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 30: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

LEMBAGA DAN PROFESI PENUNJANG PASAR MODAL Capital Market Supporting Institutions

NAMA DAN ALAMAT LEMBAGA DAN ATAU PROFESI PENUNJANG PASAR MODAL

NAME AND ADDRESS OF CAPITAL MARKET SUPPORTING INSTITUTION AND OR PROFFESION

NAMA & ALAMATNAME & ADDRESS

JASA YANG DIBERIKANUSEFULNESS

TARIF / FEE(�dak termasuk

pajak)

AKUNTAN PUBLIK / PUBLIC ACCOUNTANT

TJAHJADI & TAMARA

Anggota Morison Interna�onal / Member of Morison Interna�onal

Gedung Jaya, Lantai 4Jl. M H Thamrin No. 12Jakarta Pusat 10340Telp. : (62-21) 3190-8550Fax : (62-21) 3190-8502

Melakukan audit atas laporan keuangan Perseroan, termasuk melakukan stock-opname ke k a n t o r - k a n t o r c a b a n g Perseroan.

To audit Company's financial statement inc luding stock opname in branch offices of the Company.

220.000.000

(Rp)

PERIODE PENUGASAN

ASSIGNMENT PERIOD

No.No.

1. Tahun buku 2018

Book year 2018

BIRO ADMINISTRASI EFEK / SHARE REGISTRAR

PT SIRCA DATAPRO PERDANA

Wisma Sirca Jl. Johar No. 18, MentengJakarta 10340Telp. : (62-21) 390-0645, 390-5920Fax : (62-21) 314-0185, 390-0671

Administrasi saham Per-seroan atas data pemegang saham bulanan dan recording date.

To manage recording Company's shares which is related to monthly shareholders data and recording date.

51.500.0002. Periode per tahun,

dimulai pertengahan

tahun.

Yearly, starts in the mid of

the year.

PT KUSTODIAN SENTRAL EFEK INDONESIA(INDONESIAN CENTRAL SECURITIES DEPOSITORY)

Gedung Bursa Efek Indonesia, G e d u n g 1 Lt . 5 J l . J e n d e ra l Sudirman Kav. 52-53

Sebagai pendukung/pelaksana manakala Perseroan melakukan corporate ac�on.

As executor/supporter when the Company caries out corporate ac�on.

10.000.0003.Periode per

tahun.

Yearly

NOTARIS / NOTARY

Dr. Irawan Soerodjo,S.H.,M.Si.

Jl. KH. Zainul Arifin No.2Komplek ketapang Indah B2No. 4-5 Jakarta 11140Telp. : (62-21) 6301511 Fax : (62-21) 6337851.

Pembuat notulen dan berita acara rapat umum pemegang saham tahunan, serta mengurus dokumentasi terkait.

To make minutes and the official report of the annual general shareholders mee�ng, and the documenta�on concern.

149.771.250

4.

Periode per tahun.

Yearly

03

Profil Perusahaan Company Profile

50 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 31: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Information of the Company Website

INFORMASI PADA WEBSITE PERSEROAN

Dengan diberlakukannya Peraturan OJK No. 8/POJK.04/2015 tentang website Emiten atau perusahaan publik, Perseroan telah melengkapi website perusahaan dengan beberapa Informasi pen�ng seper� Informasi pemegang saham, kode e�k, struktur perseroan laporan keuangan lima tahun terakhir, selain itu website Perseroan juga memuat Informasi produk dan layanan yang diberikan Perseroan. Informasi yang diberikan senan�asa diperbaruhi secara berkala.

With the enactment of OJK Regula�on No. 8 / POJK.04 / 2015 concerning the Issuer or public company website, the Company has completed the company's website with several important informa�on such as shareholder Informa�on, code of ethics, the company's financial report structure for the last five years, besides the Company's website also contains informa�on on products and services given by the Company. The informa�on provided is constantly updated regularly.

SERTIFIKASI Certification

Sebagai perseroan yang bergerak di bidang distribusi produk farmasi, maka Perseroan harus patuh pada peraturan yang dikeluarkan oleh Badan Pengawas Obat dan Makanan (BPOM) diantaranya keharusan untuk melakukan implementasi aturan Cara Distribusi Obat yang Baik (CDOB). Proses untuk mendapatkan ser�fikasi CDOB di semua cabang masih terus diupayakan. Berbagai pembenahan yang mendukung pencapaian operasional yang sesuai dengan persyaratan CDOB dilakukan dengan sungguh-sungguh bahkan di kantor pusat telah dibentuk �m tugas (task force) agar dapat lebih fokus dalam membantu pencapaian ser�fikat CDOB. Puji syukur kepada Tuhan yang Maha Esa, karena dengan kerja keras dari semua karyawan cabang dan �m tugas, maka di tahun 2018 total cabang yang berhasil mendapat ser�fikat CDOB menjadi 25 cabang, diharapkan pada tahun 2019 semua cabang dapat berhasil mendapatkan ser�fikat CDOB.

As a company engaged in the distribu�on of pharmaceu�cal products, we must comply with the regula�ons issued by the Food and Drug Supervisory Agency (BPOM) including the necessity to implement the requirements for Good Distribution Practice (GDP). The process of ge�ng GDP cer�fica�on in all branches is s�ll being sought. Various improvements that support opera�onal achievement in accordance with GDP requirements are carried out seriously even at the head office where a task force has been formed in order to be more focused in assis�ng in achieving GDP cer�fication. Thank you to God Almighty, because with the hard work of all branch employees and task teams, in 2018 the total branches that have successfully obtained GDP Cer�fication become 25 branches, it is expected that by 2019 all branches can successfully obtain a GDP Cer�fication.

CDOB

Profil Perusahaan Company Profile

51PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY

Page 32: PROFILE PERUSAHAAN · Board of Directors to increase issued capital and paid-up capital from Rp 72,800,000,000 to Rp 127.400.000.000 simultaneously to change certainty of Arcle 4

Sebagai perseroan yang sudah menerapkan sistem managemen mutu (ISO 9001) sejak tahun 2012, perseroan terus melaksanakan semua ketetapan secara konsisten dalam pengelolaan perusahaan baik di �ngkat pusat maupun cabang. Bahkan, Perseroan juga sudah menyesuaikan dengan aturan/standar Management Mutu yang terbaru yaitu ISO 9001 : 2015 sejak tahun 2017. Adapun perbedaan utama antara versi 2008 dengan versi 2015 yang saat ini diterapkan di perseroan adalah Pengelolaan Resiko dan Peluang Usaha. Semua bagian sudah memiliki Da�ar Resiko dan Peluang dan dilakukan evaluasi secara berkala. Selain itu ditetapkan juga Sasaran Mutu dari semua bagian dan dilakukan monitoring hasilnya se�ap bulan. Untuk memas�kan semua ketetapan ISO 9001 : 2015 dilaksanaan secara konsisten, �m Audit Mutu Internal (AMI) diterjunkan. Sepanjang tahun 2018 telah melakukan 3 (�ga) kali AMI. Semua ketetapan dilakukan secara konsisten dan terukur. Pada tahun 2018 juga telah dilakukan audit surveillance oleh Badan Ser�fikasi yang ditunjuk dengan hasil sangat memuaskan.

As a company that has implemented a quality management system (ISO 9001) since 2012, the company con�nues to implement all provisions consistently in managing the company both at the central and branch levels. In fact, the Company has also switched to the latest version Quality Management standards / rules, namely ISO 9001: 2015 since 2017. The main difference of the new version currently applied in the company is Risk Management and Business Opportuni�es. All units already have a Risk and Opportunity List and are regularly evaluated. In addi�on, the Quality Goals of all units are also s�pulated and the results are monitored every month. To ensure that all ISO 9001: 2015 provisions are implemented consistently, the Internal Quality Audit (AMI) team is deployed. Throughout 2018 AMI has been held 3 (three) �mes. All provisions are carried out consistently and measurably. In 2018 an surveillance audit was conducted by the appointed Cer�fica�on Body with very sa�sfactory findings.

ISO 9001

03

Profil Perusahaan Company Profile

52 PT MILLENNIUM PHARMACON INTERNATIONAL TbkLaporan Tahunan 2018 | Annual Report DEFY GRAVITY